All News
RETRO - Taper or Not: You Decide
A prospective, phase 3 trial of rheumatoid arthritis (RA) patients in sustained remission has shown more than half will flare if disease-modifying antirheumatic drugs (DMARD) therapy is tapered or discontinued and that remission is best maintained by continued DMARD therapy.
Read Article
Diagnositic Imaging comparison in 36 acute Gout vs CPPD pts:
- Better: MSK US sensitivity/specificity for gout 92%/83% & 91%/92% for CPPD
- Less: DECT sensitivity/specificity for gout 63%/92% & 55%/92% for acute CPPD https://t.co/Ee2MFb8qyl
Links:
Dr. John Cush RheumNow ( View Tweet)
Low dose #methotrexate in primary cardiac prevention #CIRT. Trial had LESS decline in GFR in those with mild renal impairment than placebo. ?meaningful or a fluke. Either way MTX can be used safely in mild CRF! Just follow creatinine/GFR. #ClinicalPearl @RheumNow https://t.co/SyfsxZEeUH
Janet Pope Janetbirdope ( View Tweet)
As a loud, fast talking man that has no idea what he’s talking about, I can vouch for this. https://t.co/0pjuzHhEBK
Ethan Craig rheumecraig ( View Tweet)
The heterogeneous 🌍🌎🌏 world prevalence of systemic #lupus reflects heterogeneity in:
➡️ Ethnic mix
➡️ Genetic background
➡️ Age & sex
➡️ Year of the study
➡️ Socio-economic factors
➡️ Epidemiological methods
➡️ Environmental factors (?)
Across populations https://t.co/QMJbJUf3vD
Laurent ARNAUD Lupusreference ( View Tweet)
Excited to share that the 2nd ed. Musculoskeletal Ultrasound in Rheumatology Review is the #1 new release in ultrasonography books on @amazon #ultrasound #RheumTwitter #meded #MedTwitter #POCUS #FOAMed https://t.co/b0ptm3MKid
Minna Kohler, MD, RhMSUS minnakohlermd ( View Tweet)
Upadacitinib was shown to be effective in two Phase 3 SELECT-AXIS trials. 1st trial: in bDMARD-IR AS pts the ASDAS resp was 44% vs 10% PBO at wk 14). 2nd trial: in nr-axSpA, the ASDAS response at wk 14: 42% vs 18% PBO. https://t.co/rnv9VVITeE
Links:
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib (oral TYK2 inhibitor) in development, has been shown to be highly effective in psoriasis & PsA, but failed to meet its primary endpoints at wk 12 (remission) in Ulcerative Colitis in the phase 2 LATTICE-UC trial vs placebo https://t.co/ZGYuozFgOk
Links:
Dr. John Cush RheumNow ( View Tweet)
Check out the most recent podcast where we “Ask Cush Anything” and discuss a dozen news items from the last week.
https://t.co/Xb81eWEZ1q
#RheumNow
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Associations with Myositis Antibodies
Read the full post on #RheumNow
https://t.co/tzPU1scc8x https://t.co/F537tPAQTU
Links:
Dr. John Cush RheumNow ( View Tweet)
WHO's Strategic Advisory Group on immunisation has advised an addition COVID vaccination in those >60 years and the immunosuppressed (due to a higher risk of breakthrough infections) https://t.co/NcGr8EMDaO
Links:
Dr. John Cush RheumNow ( View Tweet)
The CDC estimates of the national prevalence of arthritis and arthritis-attributable activity limitations (AAAL) show a continued increase in absolute number: 58.5 million US adults have arthritis, 25.7 million of whom have AAAL.
Read more on #RheumNow
https://t.co/9RNIduVCZh https://t.co/fzxWMbcEfU
Links:
Dr. John Cush RheumNow ( View Tweet)
Most common reasons for starting canakinumab? Survey of 58 MDs (caring for 147 febrile pts) 1) perceived efficacy(81%), 2) lack of prior response (41%), 3) good safety (40%). Efficacy w/ HIDS/MKD (91%), no response w/ FMF (52%) https://t.co/JjxaUyBnyB
Links:
Dr. John Cush RheumNow ( View Tweet)
Clinical Associations with Myositis Antibodies
Read the full article on #RheumNow
https://t.co/tzPU1scc8x https://t.co/xxF1gIulwY
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Several studies have suggested that biologic Rx of Psoriasis may lower risk of later PsA. New study of nearly 2 million PSO (15k given biologic, 20K given oral Rx). The risk developing PsA higher w/ biologic (aHR 4.48) vs oral or phototherapy https://t.co/Na5EfWelkY https://t.co/0sL18UWjhO
Links:
Dr. John Cush RheumNow ( View Tweet)
We are reviewing cases from Ask Cush Anything and almost a dozen news items and reports on this week’s podcast. Download today.
https://t.co/Xb81eWEZ1q https://t.co/K6zPKtwAD7
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: An erosive hand osteoarthritis (EOA) study from the Osteoarthritis Initiative shows that EOA is more common in older women and is strongly linked to further progressive, articular structural damage.
https://t.co/XOVKNj423l
#RheumNow https://t.co/CYxW6mJpCH
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
Upadacitinib RA program (5306 pts) the risk of H. zoster by Rx and dose (HZ/100PYs)
MTX = 0.8/100PY
ADA+MTX= 1.1/100PY
UPA 15 mg= 3.0/100PY
UPA 30 mg = 5.3/100PY
Hence there is a 4-5X risk of HZ w/ JAKinhibitors
https://t.co/wo9ih5PJ77
#RheumNow https://t.co/h1GoGzADdv
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:
“Hiker’s feet” newly proposed cutaneous foot manifestations of dermatomyositis. Most pts had the antisynthetase syndrome (with anti-Jo-1) and almost all had mechanic’s hands. Such findings should prompt a search for ILD https://t.co/98EAQUHJbz https://t.co/Cw6rSIUyW2
Links:
Dr. John Cush RheumNow ( View Tweet)
